In addition, the expression of IL-4, IL-13, CXCL10, CCL5, CCL17, and CCL22, which are atopic dermatitis mediators, increased 2- or 3-fold in HaCaT cells treated with DPM compared with that in the control group. This evidence concerns the gene IL13 and atopic eczema.